MAGPIE Study: A genomic test intervention designed to provide patients with personalised melanoma, bowel, breast, and prostate cancer screening information
-
Study Coordinator
Dr. Sibel Saya,
+61 3 8559 7189
Project Details
Skin melanomas, breast, bowel, and prostate cancer were the most diagnosed cancers in Australia in 2019. The MAGPIE (Multi-cAncer genomic risk assessment to target screening in General PractIcE) study is the first of its kind in the world, aiming to pilot the use of a multi-cancer polygenic risk score (DNA test) in primary care. MAGPIE will determine how primary care patients use the information from a multi-cancer DNA, which provides their personalised risk of multiple cancers, along with tailored cancer screening recommendations. It aims to determine how best to deliver this risk and screening information to ensure it helps people make the best decision about doing cancer screening tests.
Researchers
Dr. Sibel Saya, Study Coordinator/ Research Fellow, University of Melbourne
Herman Prof Jon Emery, Academic GP, University of Melbourne
Prof Mark Jenkins, Genetic Epidemiologist, University of Melbourne
Dr. Ingrid Winsnip, Investigator, University of Melbourne
A/Prof Daniel Buchanan, Genetic Pathologist, University of Melbourne
Dr. Paul James, Clinical Geneticist, Peter MacCallum Cancer Centre & University of Melbourne
Dr. Laura Forrest, Research Fellow/Genetic Counsellor, Peter MacCallum Cancer Centre & University of Melbourne
A/Prof. Jennifer McIntosh, Implementation Scientist, University of Melbourne
Prof Melissa Southey, Molecular Geneticist, Monash University
Dr. Richard Allman, Chief Scientific Officer, GeneType Pty Ltd
Dr. Daniel Lee, Radiologist, Imaging Associates
Dr. Amelia Smit, Research Fellow, University of Sydney
Prof Anne Cust, Cancer Epidemiologist, University of Sydney
Dr. James Dowty, Statistician, University of Melbourne
Ms. Rachel Brooks, Research Nurse, University of Melbourne
Mr. Matthew Thoenig, Research Officer, University of Melbourne
Ms. Zoe Siviour, Research Assistant, University of Melbourne
Collaborators
GeneType (Genetic Technologies Limited)
Funding
This study is funded by Cancer Council Victoria and the University of Melbourne